ArticleBrain and behavior2026
Association of Blood-Based Biomarkers and Malignant Infarction in Severe Anterior Circulation Ischemic Stroke.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo determine the association of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) with the development of a malignant infarction in severe anterior circulation ischemic stroke.
methodsIn this prospective, single-center cohort study, patients with severe acute ischemic stroke due to large vessel occlusion (LVO) in the anterior circulation were included. Malignant infarction was defined by clinical and neuroradiological parameters. Serum biomarkers levels of NfL and GFAP were determined by ultrasensitive ELISA. Univariable and multivariable logistic regression models, along with receiver operating characteristics (ROC) characteristic analyses, were performed to assess the predictive value of sNfL and sGFAP.
resultsBetween 06/2020 and 09/2022, 383 patients were included [54.6% female, median age 79 (interquartile range, (IQR) 69-84) years, median NIHSS Score on admission 14 (IQR 9-17)]. Biomarker serum levels were measured at a median of 36 [IQR 23-61] hours after symptom onset. Malignant infarction occurred in 83 patients (21.7%). Both sNfL and sGFAP levels were significantly elevated in patients with compared to those without malignant infarction (sNfL: 208 pg/ml vs. 96 pg/ml, p < 0.001; sGFAP: 36.6 ng/ml vs. 4.1 ng/ml, p < 0.001). After adjusting for clinical and radiological parameters, sNfL and sGFAP remained independent predictors for malignant infarction (sNfL: OR 2.91 [1.55-5.45], p < 0.001; sGFAP: 3.49 [1.80-6.75], p < 0.001). The inclusion of both biomarkers in prediction models significantly improved their predictive value.
conclusionsSerum NfL and GFAP independently predict malignant infarction in severe anterior circulation ischemic stroke, albeit with only a low effect size in models with established prognostic factors. Further studies investigating earlier and serial biomarker measurement are required to improve prognostic models supporting risk stratification and decision making. STUDY REGISTRATION: DRKS00022064.In severe anterior circulation ischemic stroke due to LVO, sNfL and sGFAP levels were significantly elevated in patients who developed malignant infarction. Both biomarkers independently predicted malignant infarction after adjustment for clinical and radiological factors. Nevertheless, the additional predictive value beyond established prognostic parameters was modest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.